FDA Accepts Supplemental NDA for Travere's Filspari (Sparsentan)
The FDA has accepted a supplemental NDA for Filspari (Sparsentan) from Travere.
Company
Pharmaceutical intelligence for Travere Therapeutics with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.